Latest news with #NK
The Verge
3 days ago
- Health
- The Verge
Young people sue Donald Trump over climate change
A group of young people — as young as 7 and as old as 25 — are suing the Trump administration to stop its assault on renewable energy and climate action. Executive orders President Donald Trump signed to promote fossil fuels amount to an 'unconstitutional' overreach of power, they allege in a complaint filed Thursday at a US District Court in Montana. The 22 plaintiffs also claim that by increasing pollution and denying climate science, the president's actions violate their Fifth Amendment rights to life and liberty. It's the latest high-profile case brought against governments by youth concerned about how fossil fuel pollution and climate change poses risks to their health and ability to thrive as they grow up. Two brothers, aged 11 and 7, 'were born into climate change-induced smoke seasons that did not exist for older generations' Two brothers, aged 11 and 7 and named 'J.K.' and 'N.K.' in the suit, 'were born into climate change-induced smoke seasons that did not exist for older generations and which compromise their health,' the complaint says. They grew up mostly in Montana but now live in Southern California, and the suit says wildfire smoke has encroached on their lives from state to state. J.K. was born with an abnormal mass of lung tissue and 'experienced nosebleeds, sore throats, headaches, tiredness, coughing, trouble breathing, and eye irritation from wildfire smoke,' according to the suit. N.K. has 'frequent' upper respiratory infections that have led to emergency room visits. They've both missed school days and camp because of feeling sick from smoke and soot in the air from wildfires, it says. Greenhouse gas emissions from fossil fuels trap heat, and rising temperatures have contributed to longer fire seasons in the western US. With hotter, drier conditions, the area burned by forest fires in the western US doubled between 1984 and 2015. 'Every additional ton of [greenhouse gas] pollution and increment of heat Defendants cause will cause J.K. and N.K. more days of poor air quality, more smoke, and thus, more harm to their lives, health, and safety,' the complaint adds. In recent years, scientists have been trying to better understand the long-term health impact of wildfire smoke, which previously hadn't been studied as thoroughly as pollution from other sources thought to be more consistent problems, like factories and highways. Now, chronic exposure to wildfire smoke is a growing concern. Wildfire smoke is considered a neurotoxin estimated to be more harmful than other common air pollutants, but its effects on the body can vary depending on what kinds of materials burn and how chemicals released by the fire interact with other substances in the atmosphere. After campaigning on a promise to ' drill, baby, drill ' and accepting more than $75 million in contributions from oil and gas interests, Trump signed executive orders on his first day in office declaring a purported 'national energy emergency,' directing federal agencies to 'unleash' domestic fossil fuel production and promote the use of gas-powered vehicles over EVs. He signed another executive order to 'reinvigorat[e]' the coal industry in April. Coal releases more planet-heating pollution when burned than other fossil fuels and has struggled to compete with cheaper sources of electricity. The plaintiffs are seeking injunctive relief to block implementation of those executive orders and to declare them unconstitutional. They also claim that Trump lacks the authority to erode environmental protections passed by Congress under the Clean Air Act. The administration's efforts to impede scientific research and remove climate information from federal websites amounts to 'censorship' and denies plaintiffs access to resources they might otherwise be able to use to minimize risks they face from climate change, the suit alleges. In response to the lawsuit, White House assistant press secretary Taylor Rogers said in an email to The Verge, 'The American people are more concerned with the future generations' economic and national security, which is why they elected President Trump in a landslide victory to restore America's energy dominance. Future generations should not have to foot the bill of the lefts' radical climate agenda.' The plaintiffs, who hail from Montana, Oregon, Hawai'i, California, and Florida, are represented by the nonprofit law firm Our Children's Trust, which has also represented young people in similar climate cases. A federal appellate court dismissed another case that youth filed against the Obama administration in 2015 over fossil fuel pollution causing climate change, and the US Supreme Court ended that legal battle this year when it declined to hear an appeal. But there have also been some wins. A group of youth reached a settlement last year with the state of Hawai'i and its Department of Transportation that commits them to a plan to reach zero greenhouse gas emissions from transportation by 2045. J.K. and N.K. were also plaintiffs in a climate suit filed against the state of Montana. Last year, Montana's Supreme Court upheld a district judge ruling affirming their right to a clean and healthy environment and rejecting policies that had barred officials from considering the consequences of climate change when permitting new energy projects.
Yahoo
24-05-2025
- Automotive
- Yahoo
BMW Begins Solid-State Battery EV Testing
Solid-state batteries are considered the inevitable future of EVs, but bringing them to market is slow work. One of Germany's most popular automakers is no stranger to putting in the legwork, as the i7 M70 you see before you is sporting batteries that have been in development since at least 2016. The automaker plans to road test the vehicle extensively on the streets of Munich. View the 3 images of this gallery on the original article Let's start with the how. Back in 2016, BMW began cooperating with battery manufacturing company Solid Power. In mid-2021, that commitment escalated, with the Bavarians (along with Ford) formally investing in Solid Power's Series B funding. At the end of 2022, the two grew even closer, as BMW kicked off a cell prototype production line with Solid Power's insight. Today, we feast our eyes on the result: a BMW i7 M70 fitted with solid-state batteries that were reportedly developed via the partnership. Interestingly, the solid-state batteries here have more in common with the EVs BMW currently sells, rather than the upcoming Neue Klasse (NK) models. NK vehicles rely on cylindrical cells that are more tightly packed with no modules, whereas current BMW EVs use a prismatic design with modules. BMW calls this fifth-generation technology 'proven,' which is likely the reason it opted to use it over the much newer sixth-generation batteries. BMW says the i7 tester will hopefully give insight into two main areas: how to manage cell expansion as well as temperature and pressure conditioning. The advantages of solid-state batteries are significant. They offer higher energy density and lower overall weight than the batteries in use today. That translates to better range and performance. Solid-state batteries are also more resistant to extreme temperatures, making them less of a fire risk and, at an even more basic level, improving perceived resiliency on the customer side. The biggest current downside is cost. The automaker quipped back in February that solid-state tech is simply too expensive to roll out, claiming customers wouldn't be willing to shell out the extra coin needed to make solid-state batteries a reality. At least, not for now. Around the same time, rival Mercedes-Benz said it was 'close' to putting solid-state batteries into production. Similarly, the Affalterbach-based automaker is testing an EQS fitted with 'semi-solid-state batteries.' Solid-state batteries may be the future, but there's still a lot of room for improvement when it comes to traditional lithium-ion tech. Look no further than BMW's own Neue Klasse cars, which are projected to offer as much as 500 miles of range or more on a full charge. Ultimately, it's unlikely we'll see a production-ready car powered by a solid-state battery this decade. After all, those product roadmaps have largely already been written. But with some manufacturers clearly looking to the future, it's reasonable to expect this niche to naturally evolve in the next ten years. Expect a low-batch or super-lux vehicle to pilot the tech at a high price, followed by a slow trickle down. Whether or not Mercedes will beat BMW to the punch is anyone's guess. BMW Begins Solid-State Battery EV Testing first appeared on Autoblog on May 21, 2025
Business Wire
15-05-2025
- Business
- Business Wire
Innate Pharma Highlights ANKET ® Abstracts Selected for the EHA 2025 Congress
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') today announced that an abstract regarding IPH6501, its ANKET ® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy. Abstract details Antitumor characterization of IPH6501, a novel il2v-armed tetraspecific NK cell engager targeting CD20 B cells, in DLBCL and FL patient samples, and in preclinical combination with R-CHOP Abstract Code: PS2004 Session: Poster session 2 Session Date/Time: Saturday, June 14, 2025, 18:30 – 19:30 CEST More information can be found on the EHA website. In addition, an abstract related to SAR'514/IPH6401 (developed by Sanofi) was accepted for online publication. Abstract Code: PB2850 About ANKET ® ANKET ® (A ntibody-based NK cell E ngager T herapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer. This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. About IPH6501 IPH6501 is the first Antibody-based NK cell Engager Therapeutic to co-engage activating receptors on NK cells (NKp46 and CD16), IL-2R (but not the alpha subunit) through a variant of human IL-2, and a tumor antigen (CD20) via a single molecule, hence providing proliferation and activation signals targeted to NK cells and promoting their cytotoxic activity against CD20 expressing malignant cells. IPH6501 has shown better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models (Demaria, EHA 2023, Carrette, SITC 2024, Demaria et al, Science Immunology 2024). IPH6501 is currently being evaluated in a Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with relapsed and/or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at Follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Business Insider
14-05-2025
- Business
- Business Insider
Exelixis initiated dose-escalation stage of first human Phase 1 study of XB628
Invenra 'announced that its collaboration partner, Exelixis (EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer cell engager that targets NK group 2 member A, an inhibitory receptor on NK cells, and programmed cell death-ligand 1. The molecule was discovered in part through a collaboration between Exelixis and Invenra.' Protect Your Portfolio Against Market Uncertainty
Yahoo
13-05-2025
- Business
- Yahoo
Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors
MADISON, Wis., May 13, 2025--(BUSINESS WIRE)--Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ: EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1). The molecule was discovered in part through a collaboration between Exelixis and Invenra. About Invenra Inc. Invenra Inc. pioneers the discovery and development of next-generation multispecific antibodies to address unmet therapeutic needs. At the core of Invenra's innovation is the proprietary B-Body® platform, a highly developable bispecific antibody scaffold engineered for superior yield, purity, stability, and compatibility with standard manufacturing processes. This platform enables the rapid generation of bispecific and multispecific antibodies with excellent biophysical properties, facilitating their progression from discovery through clinical development. To further accelerate antibody development, Invenra offers the B-Body Express™ Antibody Expression service, providing partners with swift access to high-quality bispecific antibodies derived from their own sequences. This service delivers fully QC-analyzed antibodies within weeks, supporting expedited preclinical research timelines. Invenra collaborates with pharmaceutical and biotechnology companies worldwide, contributing its expertise in antibody discovery and development. The company's participation in industry events, such as PEGS Boston, underscores its commitment to advancing bispecific antibody technologies and fostering partnerships that translate innovative science into transformative therapies. View source version on Contacts Bryan Glaser, Vice President of Business Developmentbglaser@ 608-441-8319https:// Sign in to access your portfolio
